Co-Chief Executive Officer and Chief Financial Officer
Susan is an accomplished senior level executive with extensive experience in investing, financing, planning and business development for public and private companies, family offices and hedge funds. She held a number of senior finance, treasury and business development positions at Joseph E. Seagram, a global alcoholic beverage and media company. After more than a decade at Seagram, Susan became the Chief Financial Officer for the Heyman Family Office, a multi-billion dollar family controlled organization, where she provided strategic and financial leadership across diversified business holdings, including chemical, building material and real estate operating companies, as well as for other actively managed investment activities. She also held senior executive positions in operating divisions owned by the Heyman Family, including GAF Corporation, Building Materials Corporation of America and International Specialty Products. Most recently, Susan served as Managing Director and Chief Financial Officer for Octavian Advisors, a $1 billion hedge fund. She received her bachelor's degree from the Wharton School and an MBA from Columbia Business School. She has served on numerous boards, including Greyston Bakery, a nationally recognized pioneer in Social Enterprise, and the Ovarian Cancer Research Fund, and was a Trustee for the Citizens Budget Commission.
Co-Chief Executive Officer and Chief Operating Officer
Eric is a proven business leader with over thirty years of pharmaceutical executive experience in product development, commercialization, business development and medical affairs. Eric began his career at Pfizer where he held executive roles in global and US markets for more than a twenty year period. At Pfizer, Eric’s leadership responsibilities spanned thirteen therapeutic categories encompassing over thirty brands from specialty to blockbuster products. During this time, he led five major product launches and re-launched Zithromax, turning an underperforming asset into a billion dollar U.S. franchise. In addition, he had commercial leadership responsibility for four of the five Pfizer U.S. business divisions with annual revenue ranging from $2.3 to $5.2 billion, that included products such as Celebrex, Lyrica, Viagra, Detrol, Zyrtec, and Spiriva. He also led eight major Pfizer business alliances as well as the multi-billion post-acquisition integration of Pharmacia into the Pfizer US organization. After Pfizer, Eric was appointed President of the newly created Commercial Services Division at inVentiv Health where he led a 3,500 person organization providing a broad range of service offerings to the pharmaceutical industry. After inVentiv Health, Eric served as COO for Optimer Pharmaceuticals where he was responsible for directing corporate strategy, managing business operations and supporting the successful sale of the Company to Cubist Pharmaceuticals. He received his bachelor's degree in pharmacy from Rutgers College of Pharmacy and an MBA from the Wharton School. Eric is also intimately involved with Special Olympics and Challenger League Baseball as a father of a special needs son.
Judith E. Tytel
General Counsel and Chief Compliance Officer
Judi is an attorney with deep knowledge of the pharmaceutical business. Following tenures at Carter, Ledyard & Milburn, and as General Counsel to Long Island University, Judi joined Pfizer as a policy advisor to the Chairman. She has almost twenty-five years of experience at Pfizer, culminating in the leadership of all attorneys supporting the U.S. commercial business. She helped shape the launches of Lipitor, Viagra, Zithromax, and Norvasc, among many others. Judi was the lead attorney on the integration of Pharmacia in 2003. She also led the commercial side of three Department of Justice investigations. She was a member of the senior leadership teams for both U.S. Sales and U.S. Medical. Her participation in strategic and tactical development in varied aspects of the pharmaceutical business makes her unique among attorneys. After Pfizer, Judi joined Covington & Burling as counsel in the food and drug group. She has held both appointive and elective office, serving as a member of the Zoning Board of Appeals and the Board of Trustees of the Village of Muttontown. She is a member of the Council of Overseers for the College of Pharmacy of Long Island University. She also served on the Board of Planned Parenthood of Nassau County and is a member of the National Council for Arts and Sciences of Washington University in and its New York Regional Council. Judi received her bachelor’s degree from Washington University in St Louis and a JD from New York University School of Law.
VP Manufacturing Operations and QA Officer
Darwin is a recognized expert in mechanical and solvent based extraction methodologies for isolating highly volatile terpenophenolic secondary metabolites from botanicals, spending the last ten years focusing on the bioactive constituents of cannabis. Darwin was an integral part of the team that developed and introduced the Dixie Botanicals brand of hemp based cannabidiol products for sale on the world market. He is a senior partner at the Plant Consulting Group, LLC, where he works with clients on both bench and commercial scales to develop cannabis extraction and refinement techniques that increase process efficiency and decrease cost of goods, permitting the separation and purification of individual cannabinoids. Following his work at Dixie, he became the Chief Technical Officer of Applied Botanical Sciences, Inc., an international cannabinoid nutraceutical company. Darwin has always been a strong proponent of cannabinoid-based treatment therapies. He is the former chair of the Hemp Industries Association’s Cannabinoid Committee, an Associate Partner with the Indian Industrial Hemp Association and is active in assisting to create and define legislation for the burgeoning cannabis industry both domestically and internationally. Darwin received his degree in Mechanical Engineering from the University of Colorado at Boulder.
Chief Commercial Officer
Margie is an accomplished healthcare marketer with 25 years of commercial and strategic leadership experience in OTC and prescription medicines in multiple therapeutic areas. Most recently, she was Vice President, Strategic Marketing, for Adamas Pharmaceuticals, Inc., responsible for positioning and commercializing Gocovri, the company’s first CNS medicine for people with Parkinson’s disease. As principal of MK Insights, a strategic health consultancy, Margie has also continued to help clients in other therapeutic spaces including cardiology, rare diseases and anti-TNF biosimilars for ulcerative colitis and Crohn’s disease. Prior to this, Margie was at Pfizer Inc. for 20 years, where she was the US Commercial Lead for medicines in a wide range of therapeutic areas and billion-dollar brands including Zyrtec, Spiriva, Aricept, Celebrex and Lyrica, as well as related pre-launch assets including biologics for pain and an abuse-deterrent opioid portfolio. As US Commercial Lead for these therapeutic areas, Margie also led several business development initiatives, including the multi-billion acquisition and integration of King Pharmaceuticals, and the building of a stand-alone business unit focused on developing and commercializing mobile-based interventions to facilitate health care system clinical decision-making in chronic pain. Margie also teaches what she practices; she has been an adjunct professor at New York University’s Masters of Science for Integrated Marketing graduate degree program for the past several years, teaching the program’s first and final core courses, Campaign Strategy and Business Planning. Margie has a BA from Yale University, and an MBA in Marketing and Finance from the NYU Stern School of Business.
Director of Cultivation
Josh oversees all grow operations of The Clinic Colorado, one of the largest marijuana cultivators in the United States. Previously, Josh worked for Nurserymen's Exchange/Bloom Rite, the largest grower of indoor flowers, fresh cut herbs and potted edibles in the country. Josh manages all grow operations at The Clinic, including product quality and quantity management for three grow locations. He is actively involved with medical cannabis research and with the Marijuana Advisory Group. He also works with the Colorado Department of Agriculture on best practices for the industry. He has in-depth knowledge of breeding and cultivating different cannabis strains. He will bring his knowledge of 131 different cannabis strains to Fiorello Pharmaceuticals. Josh received his bachelor’s degree in Horticulture at the University of Wisconsin-Madison.
Ryan is the Director of Operations for The Clinic Colorado, where he has been responsible for day-to-day operations, including oversight of retail stores, production facilities, and construction and development activities. He has been extensively involved with developing Colorado's marijuana laws and regulations as well as The Clinic's in-house regulatory compliance procedures. At their request, he has often lent his expertise to state and local governments in their development of marijuana related laws and regulations. He has testified numerous times before state and local government bodies. Ryan is a member of the State of Colorado's work group for Concentrate Production Rules and Regulations. Earlier in his career, Ryan served as the General Manager of C&D Builders, Inc., a design, development and construction management services firm. Ryan received his bachelor’s degree in Architecture with an emphasis on environmental design from the University of Colorado-Boulder.
Director of Operations
Marla is a seasoned program coordinator specializing in customized, integrated strategic and tactical solutions. Her experience spans numerous industries, with more than ten years in the entertainment and fifteen years in the pharmaceutical sectors. She has been a production stage manager for major Broadway productions and North American tours. In her fifteen years at Pfizer Inc, she led numerous business process and technology transformation endeavors. These projects included leading the Project Management Office for a closed-loop marketing initiative moving 40+ brands to a single digital platform which was accomplished ahead of schedule and under budget; implementing tollgates and best practices for globalizing commercial operations of 6 autonomous regions; and implementing a multichannel operating plan for a 50 member marketing team. As an independent consultant, she has shared her extensive knowledge with a long list of diverse clients. Marla received her bachelor’s degree from Denison University and a professional certificate in genetics/genomics from Stamford University.